2 enrolling by invitation. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Enrolling by invitation 2 |
Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction mavacamten, Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, diltiazem - Hypertrophic Cardiomyopathy (HCM) | Phase 4 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 132 | 2026-03-01 | 2026-09-15 |
| Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions early anticoagulation, late anticoagulation - Mitral Regurgitation, Atrial Fibrillation | Phase 4 | Enrolling by invitation | National Institute of Cardiology, Warsaw, Poland | 410 | 2022-03-13 | 2026-09-17 |
Atrial Fibrillation (1) · Cardiomyopathy, Hypertrophic (1) · Mitral Valve Insufficiency (1)
Cardiovascular Diseases (2) · Heart Diseases (2) · Aortic Stenosis, Subvalvular (1) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Arrhythmias, Cardiac (1) · Cardiomyopathies (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Adrenergic beta-Antagonists (1) · Bisoprolol (1) · Carvedilol (1) · Diltiazem (1) · MYK-461 (1) · Metoprolol (1)
National Institute of Cardiology, Warsaw, Poland (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (1) · Poland (1)